Eli Lilly (LLY) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool. Date Aug. 7, 2025 at 8:30 a.m. ET Call participants Chairman and Chief Executive Officer — David A. Ricks Chief Financial Officer — Lucas E. Montarce Chief Scientific and Medical Officer — Daniel M. Skovronsky President, Lilly Diabetes and Obesity — Ilya Yuffa Senior Vice President, Global Corporate Affairs — […]
Ozempic Made Weight Loss Therapy Mainstream, But Now It’s Getting Competition
Who would have ever thought that a weight loss injectable would become a household name and pop culture-adjacent phenomenon? Ozempic has become synonymous with modern weight-loss, discussed just as casually as the latest iPhone or sneaker drop. But the era of semaglutide’s unquestioned dominance seems to be slipping with more and more weight loss drugs […]
How will weight-loss jabs change the food industry?
Richard M Lee/Shutterstock Consumers are surrounded by food that is highly conducive to weight gain. No one likes dieting and very few have lasting success. But now weight-loss injections are seen as gamechangers, yielding results that seem miraculous for people who have struggled with their weight. Around the world, obesity, high blood pressure, and abnormal […]
Study sheds light on weight regain after GLP-1 discontinuation
Many patients may keep off lost pounds after stopping a GLP-1, US data suggests – Reuters
Many patients may keep off lost pounds after stopping a GLP-1, US data suggests Reuters
Why Environment Matters More When Using GLP-1 Medications
GLP-1 medications can create opportunity for change—but environment determines what lasts. Discover how context shapes habits more than motivation alone.
Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug
In a reminder of the money still available for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in series D funds to bankroll phase 2 studies of its oral GLP-1 receptor agonist.
What happens after GLP-1s and why food will matter more than ever
A University of Oxford study published in The BMJ finds users of GLP-1 drugs like Ozempic regain weight and reverse heart health improvements within two years of stopping treatment.
China-founded pharma Corxel raises up to $287M for oral GLP-1
Since its 2019 founding, Corxel Pharmaceuticals has evolved from focusing on the China market to eyeing the world. The biopharma, founded in Shanghai but now headquartered in New Jersey, has raised as much as …
Off the Scales: ‘meticulously reported’ rise of Ozempic
In 2024, the US Centers for Disease Control and Prevention published “what could well be the most important table in modern public health”, said Tom Whipple in The Times. For decades, American waistlines had been expanding “inexorably”. But the 2024 assessment of “how fat the country was” revealed a change: the “number of fat people […]